Coherence Neuro

Coherence Neuro is a neurotechnology company based in Cambridge, founded in 2022 by Dr. Ben Woodington and Dr. Elise Jenkins. The company focuses on developing therapeutic neurotechnology to treat cancer by decoding and modulating the body's bioelectronic signals. They create implantable brain-computer interfaces (BCIs) that precisely sense and stimulate neural activity to disrupt cancer progression. Their flagship product, SOMA-1, is designed to measure and modulate brain tumors like glioblastoma in real time. This innovative device represents a new class of precision bioelectronic therapies that target cancer through neural interfaces, moving away from traditional treatments like chemotherapy. Coherence Neuro's technology integrates miniaturized implantable electronics, advanced AI systems for decoding neural signals, and closed-loop feedback to personalize therapy for each patient. Coherence Neuro collaborates with clinical researchers, neurosurgeons, and institutions in neuro-oncology, aiming to make cancer a manageable condition through their work in electro-oncology. Their goal is to improve survival and quality of life for patients with aggressive cancers by leveraging the bioelectronic code of the body as a therapeutic target.

• Employees 16
• Founded 2022